SML0492
Zanamivir
≥98% (HPLC), Influenza viral neuraminidase inhibitor, powder
别名:
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H20N4O7
化学文摘社编号:
分子量:
332.31
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Zanamivir, ≥98% (HPLC)
SMILES string
CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
InChI
1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
InChI key
ARAIBEBZBOPLMB-UFGQHTETSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +30 to +40°, c = 1 in H2O
color
white to beige
solubility
H2O: 10 mg/mL, clear
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Zanamivir has been used:
- as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
- as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
- as an antiviral to study its effects on influenza B virus by plaque reduction assay
Biochem/physiol Actions
Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.
Zanamivir is an influenza viral neuraminidase inhibitor.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Carl J Heneghan et al.
BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)
To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials
Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.
Benjamin O Fulton et al.
Journal of virology, 89(23), 12226-12231 (2015-09-25)
Influenza B virus is a human pathogen responsible for significant health and economic burden. Research into this pathogen has been limited by the lack of reporter viruses. Here we describe the development of both a replication-competent fluorescent influenza B reporter
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Javier Magano
Chemical reviews, 109(9), 4398-4438 (2009-06-23)
Mila B Ortigoza et al.
mBio, 15(2), e0220323-e0220323 (2024-01-11)
The ongoing transmission of influenza A viruses (IAV) for the past century continues to be a burden to humans. IAV binds terminal sialic acids (SA) of sugar molecules present within the upper respiratory tract (URT) in order to successfully infect
Emi Takashita et al.
Antimicrobial agents and chemotherapy, 59(5), 2607-2617 (2015-02-19)
Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持